NVS · Novartis
AI read · Bad for NVS
The AI's read
The failed trial removes artery disease as a use Novartis is pursuing for this drug. Continued study for a valve condition leaves another possible use, but it does not replace the stopped work.
Novartis is stopping work on pelacarsen for heart disease after it didn’t meet goals in a major trial.
Bad for NVS
Novartis is ending pelacarsen work for artery disease after the trial missed its main goals. It will keep studying the drug for a valve condition, but the stopped program makes this bad news for Novartis.
IONS · Ionis Pharmaceuticals
AI read · Neutral
The connection
The report says Ionis discovered pelacarsen, but gives no details about Ionis's rights, payments, or business results. So this story does not change what it says about Ionis.
Get alerts for NVS
Follow Novartis (NVS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NVSFree on the App Store and Google Play, or on the web.